Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2006 2
2007 3
2008 4
2009 3
2010 3
2011 1
2012 2
2013 2
2014 3
2015 5
2016 5
2017 3
2018 4
2019 5
2020 1
2021 6
2022 4
2023 3
2024 6
2025 2
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean N. mandal (2,682 results)?
A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic.
Shapira T, Monreal IA, Dion SP, Buchholz DW, Imbiakha B, Olmstead AD, Jager M, Désilets A, Gao G, Martins M, Vandal T, Thompson CAH, Chin A, Rees WD, Steiner T, Nabi IR, Marsault E, Sahler J, Diel DG, Van de Walle GR, August A, Whittaker GR, Boudreault PL, Leduc R, Aguilar HC, Jean F. Shapira T, et al. Nature. 2022 May;605(7909):340-348. doi: 10.1038/s41586-022-04661-w. Epub 2022 Mar 28. Nature. 2022. PMID: 35344983 Free PMC article.
Here we identify and characterize a small-molecule compound, N-0385, which exhibits low nanomolar potency and a selectivity index of higher than 10(6) in inhibiting SARS-CoV-2 infection in human lung cells and in donor-derived colonoids(7). ...Notably, in the K18-human ACE …
Here we identify and characterize a small-molecule compound, N-0385, which exhibits low nanomolar potency and a selectivity index of …
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.
Parker CC, Kynaston H, Cook AD, Clarke NW, Catton CN, Cross WR, Petersen PM, Persad RA, Pugh CA, Saad F, Logue J, Payne H, Bower LC, Brawley C, Rauchenberger M, Barkati M, Bottomley DM, Brasso K, Chung HT, Chung PWM, Conroy R, Falconer A, Ford V, Goh CL, Heath CM, James ND, Kim-Sing C, Kodavatiganti R, Malone SC, Morris SL, Nabid A, Ong AD, Raman R, Rodda S, Wells P, Worlding J, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Parker CC, et al. Lancet. 2024 Jun 1;403(10442):2416-2425. doi: 10.1016/S0140-6736(24)00549-X. Epub 2024 May 16. Lancet. 2024. PMID: 38763153 Free PMC article. Clinical Trial.
FINDINGS: Between Jan 30, 2008, and July 7, 2015, 1523 patients (median age 65 years, IQR 60-69) were randomly assigned to receive short-course ADT (n=761) or long-course ADT (n=762) in addition to postoperative radiotherapy at 138 centres in Canada, Denmark, Irelan …
FINDINGS: Between Jan 30, 2008, and July 7, 2015, 1523 patients (median age 65 years, IQR 60-69) were randomly assigned to receive short-cou …
Acid resistance in Mycobacterium tuberculosis.
Vandal OH, Nathan CF, Ehrt S. Vandal OH, et al. J Bacteriol. 2009 Aug;191(15):4714-21. doi: 10.1128/JB.00305-09. Epub 2009 May 22. J Bacteriol. 2009. PMID: 19465648 Free PMC article. Review. No abstract available.
PARP-inhibition reprograms macrophages toward an anti-tumor phenotype.
Wang L, Wang D, Sonzogni O, Ke S, Wang Q, Thavamani A, Batalini F, Stopka SA, Regan MS, Vandal S, Tian S, Pinto J, Cyr AM, Bret-Mounet VC, Baquer G, Eikesdal HP, Yuan M, Asara JM, Heng YJ, Bai P, Agar NYR, Wulf GM. Wang L, et al. Cell Rep. 2022 Oct 11;41(2):111462. doi: 10.1016/j.celrep.2022.111462. Cell Rep. 2022. PMID: 36223740 Free PMC article.
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
Parker CC, Clarke NW, Cook AD, Kynaston H, Catton CN, Cross WR, Petersen PM, Persad RA, Saad F, Bower LC, Logue J, Payne H, Forcat S, Goldstein C, Murphy C, Anderson J, Barkati M, Bottomley DM, Branagan J, Choudhury A, Chung PWM, Cogley L, Goh CL, Hoskin P, Khoo V, Malone SC, Masters L, Morris SL, Nabid A, Ong AD, Raman R, Tarver KL, Tree AC, Worlding J, Wylie JP, Zarkar AM, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Parker CC, et al. Lancet. 2024 Jun 1;403(10442):2405-2415. doi: 10.1016/S0140-6736(24)00548-8. Epub 2024 May 16. Lancet. 2024. PMID: 38763154 Free PMC article. Clinical Trial.
FINDINGS: Between Nov 22, 2007, and June 29, 2015, 1480 patients (median age 66 years [IQR 61-69]) were randomly assigned to receive no ADT (n=737) or short-course ADT (n=743) in addition to postoperative radiotherapy at 121 centres in Canada, Denmark, Ireland, and …
FINDINGS: Between Nov 22, 2007, and June 29, 2015, 1480 patients (median age 66 years [IQR 61-69]) were randomly assigned to receive no ADT …
Masculinizing Testosterone Therapy Reduces the Incidence of PIK3CA-Mutant/ER⁺ Breast Cancer but Not BRCA1-Associated Triple-Negative Breast Cancer.
Wang L, Sardella BR, Thavamani A, Massicott ES, Bret-Mounet VC, Baker GM, Guzman-Arocho YD, Tobias AM, Bartlett RA, Aronson EK, Vandal SR, Liu Z, Lee J, Veta M, Wetstein SC, Aung STH, Lui ML, Cato K, Rohde CH, Gardner KL, Hibshoosh H, Bockting WO, Houghton LC, Charlton BM, Berwick SA, Smart AC, Tesch ME, Medford AJ, Peterson CW, Domogauer JD, Jia L, Clohessy JG, Tung NM, Wulf GM, Heng YJ. Wang L, et al. medRxiv [Preprint]. 2025 Sep 19:2025.09.15.25335324. doi: 10.1101/2025.09.15.25335324. medRxiv. 2025. PMID: 41001463 Free PMC article. Preprint.
MATERIALS AND METHODS: We leveraged a large human breast tissue dataset (n=417) to assess TT and terminal duct lobular unit (TDLU) involution, complemented with tissue markers (ER, PR, AR, and Ki67; n =24) and transcriptome profiling ( n =8). Preclinical mode …
MATERIALS AND METHODS: We leveraged a large human breast tissue dataset (n=417) to assess TT and terminal duct lobular unit (TDLU) in …
Selective killing of nonreplicating mycobacteria.
Bryk R, Gold B, Venugopal A, Singh J, Samy R, Pupek K, Cao H, Popescu C, Gurney M, Hotha S, Cherian J, Rhee K, Ly L, Converse PJ, Ehrt S, Vandal O, Jiang X, Schneider J, Lin G, Nathan C. Bryk R, et al. Cell Host Microbe. 2008 Mar 13;3(3):137-45. doi: 10.1016/j.chom.2008.02.003. Cell Host Microbe. 2008. PMID: 18329613 Free PMC article.
The benefit of docosahexaenoic acid for the adult brain in aging and dementia.
Salem N Jr, Vandal M, Calon F. Salem N Jr, et al. Prostaglandins Leukot Essent Fatty Acids. 2015 Jan;92:15-22. doi: 10.1016/j.plefa.2014.10.003. Epub 2014 Oct 24. Prostaglandins Leukot Essent Fatty Acids. 2015. PMID: 25457546 Free article. Review.
Given the fundamental role of ApoE in cellular lipid transport and metabolism in the brain and periphery, it is no surprise that ApoE affects n-3 PUFA brain function as well. It remains to be seen to what extent ApoE4 deleterious effect in AD is associated with n-3 …
Given the fundamental role of ApoE in cellular lipid transport and metabolism in the brain and periphery, it is no surprise that ApoE affect …
59 results